Loading...
Header Logo
Keywords
Last Name
Institution

ANIL K SOOD

TitleProfessor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2019 May 07. PMID: 31063534.
      View in: PubMed
    2. McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine. 2019 May; 43:127-137. PMID: 31056473.
      View in: PubMed
    3. Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. 2019 Apr 23. PMID: 31012964.
      View in: PubMed
    4. Abe JI, Sood AK, Martin JF. Editorial: Cardio-Oncology: From Bench to Bedside. Front Cardiovasc Med. 2019; 6:37. PMID: 31024931.
      View in: PubMed
    5. Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ. Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology. 2019 Apr 06; 106:244-251. PMID: 31005045.
      View in: PubMed
    6. Murillo OD, Thistlethwaite W, Rozowsky J, Subramanian SL, Lucero R, Shah N, Jackson AR, Srinivasan S, Chung A, Laurent CD, Kitchen RR, Galeev T, Warrell J, Diao JA, Welsh JA, Hanspers K, Riutta A, Burgstaller-Muehlbacher S, Shah RV, Yeri A, Jenkins LM, Ahsen ME, Cordon-Cardo C, Dogra N, Gifford SM, Smith JT, Stolovitzky G, Tewari AK, Wunsch BH, Yadav KK, Danielson KM, Filant J, Moeller C, Nejad P, Paul A, Simonson B, Wong DK, Zhang X, Balaj L, Gandhi R, Sood AK, Alexander RP, Wang L, Wu C, Wong DTW, Galas DJ, Van Keuren-Jensen K, Patel T, Jones JC, Das S, Cheung KH, Pico AR, Su AI, Raffai RL, Laurent LC, Roth ME, Gerstein MB, Milosavljevic A. exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. Cell. 2019 Apr 04; 177(2):463-477.e15. PMID: 30951672.
      View in: PubMed
    7. Srinivasan S, Yeri A, Cheah PS, Chung A, Danielson K, De Hoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Murthy VL, Nejad P, Paul A, Rigoutsos I, Rodosthenous R, Shah RV, Simonson B, To C, Wong D, Yan IK, Zhang X, Balaj L, Breakefield XO, Daaboul G, Gandhi R, Lapidus J, Londin E, Patel T, Raffai RL, Sood AK, Alexander RP, Das S, Laurent LC. Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell. 2019 Apr 04; 177(2):446-462.e16. PMID: 30951671.
      View in: PubMed
    8. Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 May; 18(5):969-979. PMID: 30926640.
      View in: PubMed
    9. Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. 2019 Mar 27. PMID: 30918328.
      View in: PubMed
    10. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 Jun 15; 125(12):1963-1972. PMID: 30835824.
      View in: PubMed
    11. Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecol Oncol. 2019 May; 153(2):230-237. PMID: 30797590.
      View in: PubMed
    12. Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer. Mol Ther Nucleic Acids. 2019 Feb 16; 16:118-129. PMID: 30861414.
      View in: PubMed
    13. Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS. Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clin Chem. 2019 May; 65(5):674-683. PMID: 30770374.
      View in: PubMed
    14. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 2019 Feb; 40:290-304. PMID: 30655206.
      View in: PubMed
    15. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 Jan; 20(1):e15-e28. PMID: 30614472.
      View in: PubMed
    16. Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett. 2019 Feb 01; 442:464-474. PMID: 30503552.
      View in: PubMed
    17. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018 Dec; 38:100-112. PMID: 30487062.
      View in: PubMed
    18. An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. 2019 03; 38(12):2123-2134. PMID: 30455428.
      View in: PubMed
    19. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther. 2019 02; 18(2):421-436. PMID: 30420565.
      View in: PubMed
    20. Salcedo MP, Sood AK, Dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Ramirez PT, Schmeler KM. Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecol Oncol. 2019 01; 152(1):101-105. PMID: 30396690.
      View in: PubMed
    21. Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, Park YM. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Deliv. 2018 Nov; 25(1):1394-1402. PMID: 29890852.
      View in: PubMed
    22. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 Nov 01; 4(11):1519-1526. PMID: 29860375.
      View in: PubMed
    23. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432. PMID: 30366647.
      View in: PubMed
    24. Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172. PMID: 30305341.
      View in: PubMed
    25. Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 2018 10 08; 34(4):549-560.e9. PMID: 30300578.
      View in: PubMed
    26. Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B. Bone protection by inhibition of microRNA-182. Nat Commun. 2018 10 05; 9(1):4108. PMID: 30291236.
      View in: PubMed
    27. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490. PMID: 30036226.
      View in: PubMed
    28. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435.
      View in: PubMed
    29. Zhang L, Peng D, Sood AK, Dang CV, Zhong X. Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Mol Cancer Ther. 2018 09; 17(9):1816-1823. PMID: 30181330.
      View in: PubMed
    30. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 Sep; 132(3):545-554. PMID: 30095787.
      View in: PubMed
    31. Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK. Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev. 2018 09; 37(2-3):203-211. PMID: 29948328.
      View in: PubMed
    32. Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. 2018 09; 37(2-3):439-454. PMID: 30112590.
      View in: PubMed
    33. Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YM. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. Cancer Res. 2018 Nov 01; 78(21):6247-6256. PMID: 30115698.
      View in: PubMed
    34. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923. PMID: 30050129.
      View in: PubMed
    35. González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. Activating Transcription Factor 4 Modulates TGFß-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res. 2018 Nov 15; 24(22):5697-5709. PMID: 30012564.
      View in: PubMed
    36. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2018 Oct 15; 24(20):5072-5084. PMID: 30084832.
      View in: PubMed
    37. McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu P. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst. 2018 Jul 01; 110(7):777-786. PMID: 29267866.
      View in: PubMed
    38. Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2018 06 29; 293(26):10041. PMID: 29959278.
      View in: PubMed
    39. Sharma S, Sharma P, Sachdeva MUS, Binota J, Sood A, Malhotra P, Varma N. Circulating Mature Megakaryocytes in an Unusual Case of BCR-ABL1-Positive CML. Indian J Hematol Blood Transfus. 2018 Oct; 34(4):762-764. PMID: 30369761.
      View in: PubMed
    40. Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol. 2018; 10:1758835918778483. PMID: 29977351.
      View in: PubMed
    41. Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer. 2018 Aug; 124(16):3401-3408. PMID: 29905941.
      View in: PubMed
    42. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2018 06 07; 3(11). PMID: 29889660.
      View in: PubMed
    43. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2018 06 07; 3(11). PMID: 29889661.
      View in: PubMed
    44. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2018 07 02; 128(7):3199. PMID: 29809169.
      View in: PubMed
    45. Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu S. Perioperative inhibition of ß-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain Behav Immun. 2018 10; 73:294-309. PMID: 29800703.
      View in: PubMed
    46. Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126. PMID: 29861857.
      View in: PubMed
    47. Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep. 2018 Apr 17; 23(3):823-837. PMID: 29669287.
      View in: PubMed
    48. Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 Jun 15; 78(12):3233-3242. PMID: 29661830.
      View in: PubMed
    49. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. 2018 06 11; 33(6):965-983. PMID: 29657130.
      View in: PubMed
    50. Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Res Pract Thromb Haemost. 2018 Jul; 2(3):407-428. PMID: 30046746.
      View in: PubMed
    51. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep. 2018 04 03; 23(1):297-312.e12. PMID: 29617668.
      View in: PubMed
    52. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018 04 09; 33(4):690-705.e9. PMID: 29622464.
      View in: PubMed
    53. Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res. 2018; 7:326. PMID: 29560266.
      View in: PubMed
    54. Vu HT, Kotla S, Ko KA, Fujii Y, Tao Y, Medina J, Thomas T, Hada M, Sood AK, Singh PK, Milgrom SA, Krishnan S, Fujiwara K, Le NT, Abe JI. Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. Front Cardiovasc Med. 2018; 5:23. PMID: 29594152.
      View in: PubMed
    55. Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018 03; 37(1):107-124. PMID: 29243000.
      View in: PubMed
    56. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2018; 8:9. PMID: 29456965.
      View in: PubMed
    57. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2018 02 02; 9(1):476. PMID: 29396402.
      View in: PubMed
    58. Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202. PMID: 29242937.
      View in: PubMed
    59. Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, Bar-Eli M. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun. 2018 01 31; 9(1):461. PMID: 29386624.
      View in: PubMed
    60. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res. 2018 04 15; 78(8):1923-1934. PMID: 29386184.
      View in: PubMed
    61. Filant J, Nejad P, Paul A, Simonson B, Srinivasan S, Zhang X, Balaj L, Das S, Gandhi R, Laurent LC, Sood AK. Isolation of Extracellular RNA from Serum/Plasma. Methods Mol Biol. 2018; 1740:43-57. PMID: 29388135.
      View in: PubMed
    62. Matsuo K, Machida H, Grubbs BH, Sood AK, Gershenson DM. Trends of low-grade serous ovarian carcinoma in the United States. J Gynecol Oncol. 2018 01; 29(1):e15. PMID: 29185273.
      View in: PubMed
    63. Liu Q, Lu C, Dai W, Li K, Xu J, Huang Y, Li G, Kang Y, Sood AK, Xu C. Association of biobehavioral factors with non-coding RNAs in cervical cancer. Biosci Trends. 2018; 12(1):24-31. PMID: 29553098.
      View in: PubMed
    64. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018 Feb 01; 128(2):589-606. PMID: 29251630.
      View in: PubMed
    65. Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. 2018 01 09; 10(1):212-227. PMID: 29249663.
      View in: PubMed
    66. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473. PMID: 29237804.
      View in: PubMed
    67. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795. PMID: 29212026.
      View in: PubMed
    68. Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV. MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res. 2018 01 01; 78(1):64-74. PMID: 29180471.
      View in: PubMed
    69. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci. 2018 01; 86:65-71. PMID: 29180229.
      View in: PubMed
    70. Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515. PMID: 29130936.
      View in: PubMed
    71. Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018 01; 148(1):222-232. PMID: 29132875.
      View in: PubMed
    72. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers. Sci Transl Med. 2017 Nov 08; 9(415). PMID: 29118262.
      View in: PubMed
    73. Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer. 2018 02 01; 124(3):580-586. PMID: 29112229.
      View in: PubMed
    74. Trudel-Fitzgerald C, Poole EM, Idahl A, Lundin E, Sood AK, Kawachi I, Kubzansky LD, Tworoger SS. The Association of Work Characteristics With Ovarian Cancer Risk and Mortality. Psychosom Med. 2017 Nov/Dec; 79(9):1059-1067. PMID: 28306624.
      View in: PubMed
    75. Hu X, Sood AK, Dang CV, Zhang L. The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev. 2018 02; 48:8-15. PMID: 29054012.
      View in: PubMed
    76. Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2017 10 06; 10(1):163. PMID: 28985752.
      View in: PubMed
    77. Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2017; 3:17029. PMID: 28904816.
      View in: PubMed
    78. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046. PMID: 28855350.
      View in: PubMed
    79. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505. PMID: 29228548.
      View in: PubMed
    80. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017 08 21; 8(1):310. PMID: 28827520.
      View in: PubMed
    81. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16). PMID: 28814667.
      View in: PubMed
    82. Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017; 1(1):26. PMID: 29872708.
      View in: PubMed
    83. Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb; 117(2):236-244. PMID: 28787528.
      View in: PubMed
    84. Sreedharanunni S, Varma N, Sachdeva MUS, Naseem S, Malhotra P, Bansal D, Sood A, Bose P, Varma S. Paroxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes. Eur J Haematol. 2017 08; 99(2):194-195. PMID: 28452421.
      View in: PubMed
    85. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46. PMID: 28774461.
      View in: PubMed
    86. Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W, Chen K. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis. 2017 08 01; 38(8):797-805. PMID: 28637314.
      View in: PubMed
    87. Pu T, Xiong L, Liu Q, Zhang M, Cai Q, Liu H, Sood AK, Li G, Kang Y, Xu C. Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. Oncol Lett. 2017 Sep; 14(3):2869-2877. PMID: 28928826.
      View in: PubMed
    88. Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan V. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. 2017 09 07; 130(10):1235-1242. PMID: 28679740.
      View in: PubMed
    89. Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids. 2017 Dec 15; 9:251-262. PMID: 29246304.
      View in: PubMed
    90. Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7). PMID: 28376174.
      View in: PubMed
    91. Cuneo MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology. 2017 Oct; 84:139-142. PMID: 28711723.
      View in: PubMed
    92. Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Sci Rep. 2017 06 15; 7(1):3614. PMID: 28620240.
      View in: PubMed
    93. Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan V. Role of Platelet-Derived Tgfß1 in the Progression of Ovarian Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5611-5621. PMID: 28611202.
      View in: PubMed
    94. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017 06; 36(2):199-213. PMID: 28730545.
      View in: PubMed
    95. Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin L. PRKCI promotes immune suppression in ovarian cancer. Genes Dev. 2017 06 01; 31(11):1109-1121. PMID: 28698296.
      View in: PubMed
    96. Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecol Oncol. 2017 07; 146(1):101-108. PMID: 28527672.
      View in: PubMed
    97. Chung JF, Lee SJ, Sood AK. Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget. 2017 Sep 15; 8(40):69047-69061. PMID: 28978180.
      View in: PubMed
    98. Tahlan A, Varma N, Naseem S, Bansal D, Binota J, Sood A, Sachdeva MUS, Malhotra P, Varma S. Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults. Indian J Hematol Blood Transfus. 2018 Jan; 34(1):19-24. PMID: 29398795.
      View in: PubMed
    99. Wagner MJ, Ravi V, Menter DG, Sood AK. Endothelial cell malignancies: new insights from the laboratory and clinic. NPJ Precis Oncol. 2017; 1(1):11. PMID: 29872699.
      View in: PubMed
    100. Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli S. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 2017 Apr 18; 8(16):27380-27392. PMID: 28423708.
      View in: PubMed
    101. Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res. 2017 06 01; 77(11):2903-2913. PMID: 28416487.
      View in: PubMed
    102. Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang H. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017 07; 27(7):1112-1125. PMID: 28411194.
      View in: PubMed
    103. Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 2017 Mar 21; 8(12):20145-20164. PMID: 28423620.
      View in: PubMed
    104. Kumar MNVR, Sood AK. Editorial - Metronomic chemotherapy. Cancer Lett. 2017 08 01; 400:203. PMID: 28315702.
      View in: PubMed
    105. Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH. Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2017 Mar 07; 8(10):17406. PMID: 28403581.
      View in: PubMed
    106. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123. PMID: 28265009.
      View in: PubMed
    107. Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Mol Cancer Ther. 2017 05; 16(5):966-976. PMID: 28223424.
      View in: PubMed
    108. Gangwar R, Meena AS, Shukla PK, Nagaraja AS, Dorniak PL, Pallikuth S, Waters CM, Sood A, Rao R. Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress. Biochem J. 2017 02 20; 474(5):731-749. PMID: 28057718.
      View in: PubMed
    109. Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecol Oncol. 2017 03; 144(3):496-502. PMID: 28131526.
      View in: PubMed
    110. Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. Metastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419. PMID: 28097239.
      View in: PubMed
    111. Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK. Chitosan Nanoparticles for miRNA Delivery. Methods Mol Biol. 2017; 1632:219-230. PMID: 28730442.
      View in: PubMed
    112. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519. PMID: 27992857.
      View in: PubMed
    113. Han HD, Byeon Y, Jang JH, Jeon HN, Kim GH, Kim MG, Pack CG, Kang TH, Jung ID, Lim YT, Lee YJ, Lee JW, Shin BC, Ahn HJ, Sood AK, Park YM. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep. 2016 12 02; 6:38348. PMID: 27910914.
      View in: PubMed
    114. Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1337-1351. PMID: 27828713.
      View in: PubMed
    115. Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood A, Yang P, Yeung SJ. A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integr Cancer Ther. 2017 03; 16(1):3-20. PMID: 27903842.
      View in: PubMed
    116. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904. PMID: 27903673.
      View in: PubMed
    117. Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, Guo P. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine. 2017 04; 13(3):1183-1193. PMID: 27890659.
      View in: PubMed
    118. Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, Hamilton SR, Sun B, Zhang W. MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. J Pathol. 2017 Jan; 241(1):67-79. PMID: 27741356.
      View in: PubMed
    119. Yatsenko SA, Mittal P, Wood-Trageser MA, Jones MW, Surti U, Edwards RP, Sood AK, Rajkovic A. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertil Steril. 2017 02; 107(2):457-466.e9. PMID: 27889101.
      View in: PubMed
    120. Kendricks AL, Pageon LR, Craig SL, Wen Y, Sood AK, Lockworth CR. Pathology in Practice. J Am Vet Med Assoc. 2016 Nov 15; 249(10):1149-1151. PMID: 27823375.
      View in: PubMed
    121. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 2016 11 08; 24(5):685-700. PMID: 27829138.
      View in: PubMed
    122. Han HD, Byeon Y, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YM. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine. 2016; 11:5729-5742. PMID: 27843314.
      View in: PubMed
    123. Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res. 2016 11 01; 76(21):6320-6330. PMID: 27803105.
      View in: PubMed
    124. Wang H, Li X, Volk DE, Lokesh GL, Elizondo-Riojas MA, Li L, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DG. Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery. Biotechniques. 2016; 61(5):249-259. PMID: 27839510.
      View in: PubMed
    125. Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AK. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep. 2016 11 01; 17(6):1621-1631. PMID: 27806300.
      View in: PubMed
    126. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016 Oct 20; 1(17):e87754. PMID: 27777972.
      View in: PubMed
    127. Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2016 10 19; 9(1):112. PMID: 27760566.
      View in: PubMed
    128. Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. 2016 12 15; 76(24):7194-7207. PMID: 27742688.
      View in: PubMed
    129. Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine. 2016 Oct; 12:34-42. PMID: 27720213.
      View in: PubMed
    130. Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK. Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther. 2016 12; 15(12):2894-2904. PMID: 27638860.
      View in: PubMed
    131. Huang T, Tworoger SS, Hecht JL, Rice MS, Sood AK, Kubzansky LD, Poole EM. Association of Ovarian Tumor ß2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1587-1594. PMID: 27587791.
      View in: PubMed
    132. Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016 Nov; 50:35-47. PMID: 27612280.
      View in: PubMed
    133. Abeydeera ND, Egli M, Cox N, Mercier K, Conde JN, Pallan PS, Mizurini DM, Sierant M, Hibti FE, Hassell T, Wang T, Liu FW, Liu HM, Martinez C, Sood AK, Lybrand TP, Frydman C, Monteiro RQ, Gomer RH, Nawrot B, Yang X. Evoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Res. 2016 09 30; 44(17):8052-64. PMID: 27566147.
      View in: PubMed
    134. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016 08 25; 2:16061. PMID: 27558151.
      View in: PubMed
    135. Hu Q, Cho MS, Thiagarajan P, Aung FM, Sood AK, Afshar-Kharghan V. A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets. 2017 Jan; 28(1):99-102. PMID: 27534811.
      View in: PubMed
    136. Whiting N, Hu J, Zacharias NM, Lokesh GL, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya P. Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. J Med Imaging (Bellingham). 2016 Jul; 3(3):036001. PMID: 27547777.
      View in: PubMed
    137. Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W. ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget. 2017 Oct 24; 8(51):88410-88420. PMID: 29179445.
      View in: PubMed
    138. Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. 2016 08 08; 30(2):273-289. PMID: 27478041.
      View in: PubMed
    139. Chung JF, Yoon CJ, Cheon SA, Seo ES, Park SH, Yang JS, Kim B, Joo MY, Park TJ, Kim KH, Sood AK, Lee SJ. NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. Oncotarget. 2016 Jul 26; 7(30):47576-47585. PMID: 27374093.
      View in: PubMed
    140. Matsuo K, Cahoon SS, Yoshihara K, Shida M, Kakuda M, Adachi S, Moeini A, Machida H, Garcia-Sayre J, Ueda Y, Enomoto T, Mikami M, Roman LD, Sood AK. Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstet Gynecol. 2016 Jul; 128(1):127-37. PMID: 27275802.
      View in: PubMed
    141. Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V. Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clin. 2016 Dec; 6:76-81. PMID: 27453821.
      View in: PubMed
    142. Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 07 01; 76(13):3671-5. PMID: 27527638.
      View in: PubMed
    143. Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 06 13; 29(6):874-888. PMID: 27300436.
      View in: PubMed
    144. Zhou M, Melancon M, Stafford RJ, Li J, Nick AM, Tian M, Sood AK, Li C. Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy. J Nucl Med. 2016 Nov; 57(11):1778-1783. PMID: 27283932.
      View in: PubMed
    145. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567.
      View in: PubMed
    146. Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, Sood AK, McMeekin S, Ramesh R. Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. J Biomed Nanotechnol. 2016 Jun; 12(6):1159-73. PMID: 27319211.
      View in: PubMed
    147. Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, Sood AK, Lutgendorf SK. SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget. 2016 May 31; 7(22):33179-91. PMID: 27121207.
      View in: PubMed
    148. Feng S, Kroll MH, Nick AM, Sood AK, Afshar-Kharghan V. Platelets are not hyperreactive in patients with ovarian cancer. Platelets. 2016 Nov; 27(7):716-718. PMID: 27185008.
      View in: PubMed
    149. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep. 2016 05 17; 15(7):1493-1504. PMID: 27160903.
      View in: PubMed
    150. Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2016 May 03; 7(18):25930-48. PMID: 27036018.
      View in: PubMed
    151. Bhalwal AB, Nick AM, Dos Reis R, Chen CL, Munsell MF, Ramalingam P, Salcedo MP, Ramirez PT, Sood AK, Schmeler KM. Carcinoma of the Bartholin Gland: A Review of 33 Cases. Int J Gynecol Cancer. 2016 May; 26(4):785-9. PMID: 26844611.
      View in: PubMed
    152. Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6. PMID: 26937753.
      View in: PubMed
    153. Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun; 12(12):1439-56. PMID: 27087632.
      View in: PubMed
    154. Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 2016 Apr 12; 7(15):20825-39. PMID: 26959114.
      View in: PubMed
    155. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 05 02; 126(5):1885-96. PMID: 27064283.
      View in: PubMed
    156. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016 Apr 04; 7:11169. PMID: 27041221.
      View in: PubMed
    157. Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol. 2016 Apr; 141(1):57-64. PMID: 27016230.
      View in: PubMed
    158. Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SS. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes Control. 2016 May; 27(5):661-8. PMID: 27023470.
      View in: PubMed
    159. Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SS. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. Int J Cancer. 2016 07 15; 139(2):291-9. PMID: 26934358.
      View in: PubMed
    160. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. 2016 06; 15(6):1344-52. PMID: 27009216.
      View in: PubMed
    161. Chung JF, Lee SJ, Sood AK. Immunological and pleiotropic effects of individual ß-blockers and their relevance in cancer therapies. Expert Opin Investig Drugs. 2016; 25(5):501-5. PMID: 26954371.
      View in: PubMed
    162. Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104. PMID: 26918603.
      View in: PubMed
    163. Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016 May; 141(2):260-263. PMID: 26968641.
      View in: PubMed
    164. Zhang S, Mercado-Uribe I, Sood A, Bast RC, Liu J. Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer. 2016 Mar; 7(3-4):60-72. PMID: 27382431.
      View in: PubMed
    165. Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016 Mar; 6(3):235-46. PMID: 26865249.
      View in: PubMed
    166. Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AK. SnapShot: Stress and Disease. Cell Metab. 2016 Feb 09; 23(2):388-388.e1. PMID: 26863488.
      View in: PubMed
    167. Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Mol Cancer Ther. 2016 04; 15(4):618-27. PMID: 26861249.
      View in: PubMed
    168. Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016 Mar; 56:131-143. PMID: 26849037.
      View in: PubMed
    169. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426. PMID: 26819345.
      View in: PubMed
    170. Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology. 2016 Mar; 63(3):864-79. PMID: 26599259.
      View in: PubMed
    171. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouché M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, Bütikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ceña V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222. PMID: 26799652.
      View in: PubMed
    172. Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods Mol Biol. 2016; 1402:33-41. PMID: 26721482.
      View in: PubMed
    173. Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2016; 1402:189-197. PMID: 26721492.
      View in: PubMed
    174. Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, Atkinson E, Yusuf SW, Lenihan D, Woods ML, Kies MS, Sood AK, Carmack C, Morrison WH, Gillenwater A, Sturgis EM, Garden AS. Depression and Oropharynx Cancer Outcome. Psychosom Med. 2016 Jan; 78(1):38-48. PMID: 26632757.
      View in: PubMed
    175. Mitamura T, Gourley C, Sood AK. Prediction of anti-angiogenesis escape. Gynecol Oncol. 2016 Apr; 141(1):80-5. PMID: 26748214.
      View in: PubMed
    176. Cho MS, Rupaimoole R, Choi HJ, Noh K, Chen J, Hu Q, Sood AK, Afshar-Kharghan V. Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. J Immunol. 2016 Feb 01; 196(3):1412-8. PMID: 26718342.
      View in: PubMed
    177. Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar A, Baggerly KA, Sood AK, White MA. A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol. 2015 Dec 11; 11(12):842. PMID: 26655797.
      View in: PubMed
    178. Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec 22; 13(11):2395-2402. PMID: 26686630.
      View in: PubMed
    179. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015; 6:286. PMID: 26648870.
      View in: PubMed
    180. Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 2016 Jan; 63(1):159-72. PMID: 26389641.
      View in: PubMed
    181. Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1713-24. PMID: 26581245.
      View in: PubMed
    182. Wang R, Stone RL, Kaelber JT, Rochat RH, Nick AM, Vijayan KV, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK, Chiu W. Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):14266-71. PMID: 26578771.
      View in: PubMed
    183. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79. PMID: 26493647.
      View in: PubMed
    184. Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec; 14(12):2677-86. PMID: 26516159.
      View in: PubMed
    185. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622. PMID: 26481148.
      View in: PubMed
    186. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L. Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):529-540. PMID: 26461095.
      View in: PubMed
    187. Huang T, Poole EM, Okereke OI, Kubzansky LD, Eliassen AH, Sood AK, Wang M, Tworoger SS. Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. Gynecol Oncol. 2015 Dec; 139(3):481-6. PMID: 26449316.
      View in: PubMed
    188. Thaker PH, Urbauer DL, Sood AK. Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias? Cancer. 2016 Jan 15; 122(2):325-6. PMID: 26443929.
      View in: PubMed
    189. Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77. PMID: 26313360.
      View in: PubMed
    190. Srivastava S, Misra A, Kumar D, Srivastava A, Sood A, Rawat A. Reversed-phase high-performance Liquid Chromatography-ultraviolet Photodiode Array Detector Validated Simultaneous Quantification of six Bioactive Phenolic Acids in Roscoea purpurea Tubers and their In vitro Cytotoxic Potential against Various Cell Lines. Pharmacogn Mag. 2015 Oct; 11(Suppl 3):S488-95. PMID: 26929586.
      View in: PubMed
    191. Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill SM, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukherjee S, Mills GB, Ram PT. Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. NPJ Syst Biol Appl. 2015; 1:15001. PMID: 28725457.
      View in: PubMed
    192. Jiang L, Nick AM, Sood AK. Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period? Curr Anesthesiol Rep. 2015 Sep; 5(3):250-256. PMID: 26388704.
      View in: PubMed
    193. Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer. 2015 Sep; 15(9):563-72. PMID: 26299593.
      View in: PubMed
    194. Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 01; 121(19):3444-51. PMID: 26301456.
      View in: PubMed
    195. Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AK. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer. 2015 Sep; 51(14):1978-88. PMID: 26238017.
      View in: PubMed
    196. Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9. PMID: 26227489.
      View in: PubMed
    197. Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: Future of Oncotherapy. Clin Cancer Res. 2015 Jul 15; 21(14):3121-30. PMID: 26180057.
      View in: PubMed
    198. Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015 Aug; 138(2):223-6. PMID: 26166806.
      View in: PubMed
    199. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS One. 2015; 10(7):e0131833. PMID: 26146988.
      View in: PubMed
    200. Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol. 2015 Jul; 1(4):486-94. PMID: 26181259.
      View in: PubMed
    201. Zhou M, Li J, Liang S, Sood AK, Liang D, Li C. CuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal Therapy. ACS Nano. 2015 Jul 28; 9(7):7085-96. PMID: 26098195.
      View in: PubMed
    202. Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One. 2015; 10(6):e0131095. PMID: 26098849.
      View in: PubMed
    203. Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351. PMID: 26081979.
      View in: PubMed
    204. Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer. 2015 Oct 01; 121(19):3543-50. PMID: 26096769.
      View in: PubMed
    205. Bullock MD, Silva AM, Kanlikilicer-Unaldi P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA. Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Noncoding RNA. 2015 Jun 03; 1(1):53-68. PMID: 29861415.
      View in: PubMed
    206. Matsuo K, Hom MS, Moeini A, Machida H, Takeshima N, Roman LD, Sood AK. Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecol Oncol. 2015 Aug; 138(2):332-8. PMID: 26013698.
      View in: PubMed
    207. Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25995442.
      View in: PubMed
    208. Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SK. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain Behav Immun. 2015 Nov; 50:58-62. PMID: 25989110.
      View in: PubMed
    209. Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, Sood A, Lee MH. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle. 2015; 14(14):2265-73. PMID: 25945542.
      View in: PubMed
    210. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2015 Apr 30; 520(7549):697-701. PMID: 25901683.
      View in: PubMed
    211. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97. PMID: 25878333.
      View in: PubMed
    212. Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475. PMID: 25833835.
      View in: PubMed
    213. Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8. PMID: 25827290.
      View in: PubMed
    214. Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F. STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med. 2015 Mar; 7(3):315-31. PMID: 25680860.
      View in: PubMed
    215. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015 Mar; 34(1):19-40. PMID: 25544368.
      View in: PubMed
    216. Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 2015 Feb 28; 6(6):4266-73. PMID: 25738355.
      View in: PubMed
    217. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015 Apr; 12(4):239-45. PMID: 25707631.
      View in: PubMed
    218. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 2015 Mar; 17(3):311-21. PMID: 25686251.
      View in: PubMed
    219. Kaur D, Dogra V, Thapa P, Bhattacharya A, Sood A, Sreenivasulu Y. In vitro flowering associated protein changes in Dendrocalamus hamiltonii. Proteomics. 2015 Apr; 15(7):1291-306. PMID: 25475561.
      View in: PubMed
    220. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19. PMID: 25666164.
      View in: PubMed
    221. Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65. PMID: 25502429.
      View in: PubMed
    222. Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology. 2015 Mar; 53:256-67. PMID: 25647344.
      View in: PubMed
    223. Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015 May 01; 21(9):2127-37. PMID: 25595279.
      View in: PubMed
    224. Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, Mezzanzanica D, Chen KX, Sood AK, Yang D, Zhang W. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer. 2015 Jan; 34(1):28-40. PMID: 25556616.
      View in: PubMed
    225. Srivastava A, Filant J, Moxley KM, Sood A, McMeekin S, Ramesh R. Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Curr Gene Ther. 2015; 15(2):182-92. PMID: 25537774.
      View in: PubMed
    226. Matsuo K, Yoshino K, Hasegawa K, Murakami R, Ikeda Y, Adachi S, Hiramatsu K, Yokoyama T, Nishimura M, Sheridan TB, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Fotopoulou C, Roman LD, Sood AK. Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. Gynecol Oncol. 2015 Feb; 136(2):198-204. PMID: 25497604.
      View in: PubMed
    227. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014 Dec 08; 26(6):863-879. PMID: 25490449.
      View in: PubMed
    228. Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma L. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014 Dec 05; 5:5671. PMID: 25476932.
      View in: PubMed
    229. Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, Blake P, Chirina P, Oh Jeong J, Lim H, Goy A, Pecora A, Suh KS. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 2014 Dec 05; 7:109. PMID: 25477184.
      View in: PubMed
    230. Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res. 2015 Feb 01; 21(3):602-10. PMID: 25473001.
      View in: PubMed
    231. Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L. Mind-body practices in cancer care. Curr Oncol Rep. 2014 Dec; 16(12):417. PMID: 25325936.
      View in: PubMed
    232. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59. PMID: 25416196.
      View in: PubMed
    233. Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015 Mar 01; 21(5):955-61. PMID: 25388163.
      View in: PubMed
    234. Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015 Jan; 235(1):25-36. PMID: 25230372.
      View in: PubMed
    235. van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014 Oct 29; 5:5203. PMID: 25351418.
      View in: PubMed
    236. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202. PMID: 25351346.
      View in: PubMed
    237. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092. PMID: 25277212.
      View in: PubMed
    238. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85. PMID: 25281617.
      View in: PubMed
    239. Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep; 106(9). PMID: 25214561.
      View in: PubMed
    240. Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2583-94. PMID: 25193509.
      View in: PubMed
    241. Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Rep. 2014 Sep 11; 8(5):1447-60. PMID: 25176654.
      View in: PubMed
    242. Sareen B, Bhattacharya A, Sharma M, Sood A, Ahuja PS. A simple technique for tracking individual spore and gametophyte development in Adiantum lunulatum Burm. f. using modified extra thin alginate film technique. Indian J Exp Biol. 2014 Aug; 52(8):820-4. PMID: 25141546.
      View in: PubMed
    243. Kaur D, Thapa P, Sharma M, Bhattacharya A, Sood A. In vitro flowering--a system for tracking floral organ development in Dendrocalamus hamiltonii Nees et Arn. ex Munro. Indian J Exp Biol. 2014 Aug; 52(8):825-34. PMID: 25141547.
      View in: PubMed
    244. Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila). 2014 Oct; 7(10):973-92. PMID: 25060262.
      View in: PubMed
    245. Bhandawat A, Sharma V, Sharma H, Sood A, Sharma RK. Development and crosstransferability of functionally relevant microsatellite markers in Dendrocalamus latiflorus and related bamboo species. J Genet. 2014 Jul 24; 93(2):e48-55. PMID: 25201825.
      View in: PubMed
    246. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91. PMID: 25026212.
      View in: PubMed
    247. Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9. PMID: 24952408.
      View in: PubMed
    248. Sood A, Nadha HK, Sood S, Walia S, Parkash O. Large scale propagation of an exotic edible bamboo, Phyllostachys pubescens Mazel ex H. De Lehale (Moso Bamboo) using seeds. Indian J Exp Biol. 2014 Jul; 52(7):755-8. PMID: 25059044.
      View in: PubMed
    249. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35. PMID: 24970481.
      View in: PubMed
    250. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014 Aug 28; 512(7515):431-5. PMID: 25043055.
      View in: PubMed
    251. Gizzatov A, Stigliano C, Ananta JS, Sethi R, Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P. Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett. 2014 Sep 28; 352(1):97-101. PMID: 24931336.
      View in: PubMed
    252. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Sci Transl Med. 2014 Jun 11; 6(240):240ps7. PMID: 24920658.
      View in: PubMed
    253. Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick J. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014 Dec; 8(8):1429-40. PMID: 24974076.
      View in: PubMed
    254. Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, Xue F, Zhang W. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014 Jul; 233(3):308-18. PMID: 24604117.
      View in: PubMed
    255. Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther. 2014 Aug; 15(8):1061-7. PMID: 24841852.
      View in: PubMed
    256. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014 May 05; 10:728. PMID: 24799285.
      View in: PubMed
    257. Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ikeda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, Sood AK. Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. Obstet Gynecol. 2014 May; 123(5):957-65. PMID: 24785846.
      View in: PubMed
    258. Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res. 2014 Jul 01; 74(13):3556-66. PMID: 24769442.
      View in: PubMed
    259. Davis AN, Afshar-Kharghan V, Sood AK. Platelet effects on ovarian cancer. Semin Oncol. 2014 Jun; 41(3):378-84. PMID: 25023353.
      View in: PubMed
    260. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther. 2014 Jul; 15(7):919-29. PMID: 24755674.
      View in: PubMed
    261. Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7. PMID: 24755199.
      View in: PubMed
    262. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8. PMID: 24756370.
      View in: PubMed
    263. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93. PMID: 24743243.
      View in: PubMed
    264. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48. PMID: 24709487.
      View in: PubMed
    265. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500. PMID: 24703838.
      View in: PubMed
    266. Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol. 2014 Jun; 133(3):473-9. PMID: 24674832.
      View in: PubMed
    267. Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan S. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A. 2014 Apr 08; 111(14):5331-6. PMID: 24706848.
      View in: PubMed
    268. Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang W. MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep. 2014 May; 31(5):2021-8. PMID: 24677166.
      View in: PubMed
    269. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50. PMID: 24634380.
      View in: PubMed
    270. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459. PMID: 24619206.
      View in: PubMed
    271. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. Autocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095. PMID: 24613353.
      View in: PubMed
    272. Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J Hematol Oncol. 2014 Mar 05; 7:19. PMID: 24598126.
      View in: PubMed
    273. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014 Mar; 33(1):231-69. PMID: 24696047.
      View in: PubMed
    274. Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Res. 2014 Mar 01; 74(5):1287-93. PMID: 24556724.
      View in: PubMed
    275. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, Mills GB, Sood A, Lee JS. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 2014 Feb; 34(2):811-817. PMID: 24511017.
      View in: PubMed
    276. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55. PMID: 24486585.
      View in: PubMed
    277. Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V. Perioperative beta-blocker use and survival in lung cancer patients. J Clin Anesth. 2014 Mar; 26(2):106-17. PMID: 24480297.
      View in: PubMed
    278. Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res. 2014 Sep; 24(3):182-90. PMID: 24443972.
      View in: PubMed
    279. Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6. PMID: 24384374.
      View in: PubMed
    280. Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014 May; 35(5):1100-9. PMID: 24379240.
      View in: PubMed
    281. Wang H, Heijnen CJ, van Velthoven CT, Willemen HL, Ishikawa Y, Zhang X, Sood AK, Vroon A, Eijkelkamp N, Kavelaars A. Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain. J Clin Invest. 2013 Dec; 123(12):5023-34. PMID: 24231349.
      View in: PubMed
    282. Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167. PMID: 24236104.
      View in: PubMed
    283. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan; 132(1):166-75. PMID: 24183729.
      View in: PubMed
    284. Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013 Oct 24; 155(3):552-66. PMID: 24243015.
      View in: PubMed
    285. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43. PMID: 24100628.
      View in: PubMed
    286. Wan G, Hu X, Liu Y, Han C, Sood AK, Calin GA, Zhang X, Lu X. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J. 2013 Oct 30; 32(21):2833-47. PMID: 24097061.
      View in: PubMed
    287. Lutgendorf SK, Slavich GM, Degeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J, Mendez L, Collins K, Sood AK. Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. Gynecol Oncol. 2013 Dec; 131(3):667-73. PMID: 24096110.
      View in: PubMed
    288. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target. 2013 Dec; 21(10):904-13. PMID: 24079419.
      View in: PubMed
    289. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95. PMID: 24062525.
      View in: PubMed
    290. Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):2102-9. PMID: 24045927.
      View in: PubMed
    291. Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids. 2013 Sep 10; 2:e121. PMID: 24022053.
      View in: PubMed
    292. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15. PMID: 24002999.
      View in: PubMed
    293. Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK. ß-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs. 2013 Nov; 22(11):1359-63. PMID: 23919278.
      View in: PubMed
    294. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. PMID: 23907406.
      View in: PubMed
    295. Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41. PMID: 23871637.
      View in: PubMed
    296. Gharpure KM, Sood AK. Neighborhood matters: response to EZH2 methyltransferase inhibitors. Cell Cycle. 2013 Aug 01; 12(15):2345. PMID: 23887388.
      View in: PubMed
    297. Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):E2572-81. PMID: 23798432.
      View in: PubMed
    298. Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SK. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer. 2013 Sep 01; 119(17):3234-41. PMID: 23797955.
      View in: PubMed
    299. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 2013 Sep; 130(3):565-9. PMID: 23800698.
      View in: PubMed
    300. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Jun; 23(5):815-22. PMID: 23669443.
      View in: PubMed
    301. Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013 Jul; 58(1):182-91. PMID: 23389994.
      View in: PubMed
    302. Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia. 2013 May; 15(5):502-10. PMID: 23633922.
      View in: PubMed
    303. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30. PMID: 23585472.
      View in: PubMed
    304. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. Interleukin-1ß promotes ovarian tumorigenesis through a p53/NF-?B-mediated inflammatory response in stromal fibroblasts. Neoplasia. 2013 Apr; 15(4):409-20. PMID: 23555186.
      View in: PubMed
    305. Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, Tang H, Huang TH, Liu Y, Rusch DB, Nephew KP. A new method for stranded whole transcriptome RNA-seq. Methods. 2013 Sep 15; 63(2):126-34. PMID: 23557989.
      View in: PubMed
    306. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2013; 3:58. PMID: 23519775.
      View in: PubMed
    307. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99. PMID: 23410973.
      View in: PubMed
    308. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr; 10(4):211-24. PMID: 23381004.
      View in: PubMed
    309. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013 Apr 01; 19(7):1806-15. PMID: 23386691.
      View in: PubMed
    310. Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. Why stress is BAD for cancer patients. J Clin Invest. 2013 Feb; 123(2):558-60. PMID: 23348736.
      View in: PubMed
    311. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20. PMID: 23344261.
      View in: PubMed
    312. Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91. PMID: 23321064.
      View in: PubMed
    313. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427. PMID: 24018975.
      View in: PubMed
    314. Melhem-Bertrandt A, Sood AK. Adrenergic signaling and cancer: deciphering the connections. Cancer Biomark. 2013; 13(3):131-2. PMID: 23912484.
      View in: PubMed
    315. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src activation by ß-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403. PMID: 23360994.
      View in: PubMed
    316. Thaker PH, Sood AK, Ramondetta LM. Importance of adrenergic pathways in women's cancers. Cancer Biomark. 2013; 13(3):145-54. PMID: 23912486.
      View in: PubMed
    317. Brar J, Anand M, Sood A. In vitro seed germination of economically important edible bamboo Dendrocalamus membranaceus Munro. Indian J Exp Biol. 2013 Jan; 51(1):88-96. PMID: 23441484.
      View in: PubMed
    318. Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther. 2013 Feb; 13(2):283-94. PMID: 23190436.
      View in: PubMed
    319. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11. PMID: 23200915.
      View in: PubMed
    320. Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res. 2013 Jan 01; 19(1):170-82. PMID: 23147994.
      View in: PubMed
    321. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57. PMID: 23052253.
      View in: PubMed
    322. Kloc M, Tejpal N, Sidhu J, Ganachari M, Flores-Villanueva P, Jennings NB, Sood AK, Kubiak JZ, Ghobrial RM. Inverse relationship between TCTP/RhoA and p53 /cyclin A/actin expression in ovarian cancer cells. Folia Histochem Cytobiol. 2012 Oct 08; 50(3):358-67. PMID: 23042265.
      View in: PubMed
    323. Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics. 2012 Oct; 13(13):1523-35. PMID: 23057551.
      View in: PubMed
    324. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012 Nov 10; 30(32):4026-34. PMID: 23008289.
      View in: PubMed
    325. Matsuo K, Sheridan TB, Yoshino K, Miyake T, Hew KE, Im DD, Rosenshein NB, Mabuchi S, Enomoto T, Kimura T, Sood AK, Roman LD. Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med. 2012 Oct; 1(2):156-64. PMID: 23342265.
      View in: PubMed
    326. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012 Dec 06; 120(24):4869-72. PMID: 22966171.
      View in: PubMed
    327. Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L. Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One. 2012; 7(9):e44399. PMID: 22970210.
      View in: PubMed
    328. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43. PMID: 22922531.
      View in: PubMed
    329. Wu CC, Yang TY, Yu CT, Phan L, Ivan C, Sood AK, Hsu SL, Lee MH. p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle. 2012 Sep 15; 11(18):3433-42. PMID: 22894933.
      View in: PubMed
    330. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 2012 Sep; 13(11):1034-41. PMID: 22895067.
      View in: PubMed
    331. Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, Slavich GM, Sood AK, Lutgendorf SK. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun. 2013 Mar; 30 Suppl:S126-34. PMID: 22884960.
      View in: PubMed
    332. Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, Sood AK, Ali-Fehmi R. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol. 2013 Feb; 128(2):344-8. PMID: 22871469.
      View in: PubMed
    333. You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK, Li C. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 2012 Sep 15; 72(18):4777-86. PMID: 22865457.
      View in: PubMed
    334. Zhou HY, Chen SR, Byun HS, Chen H, Li L, Han HD, Lopez-Berestein G, Sood AK, Pan HL. N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J Biol Chem. 2012 Sep 28; 287(40):33853-64. PMID: 22854961.
      View in: PubMed
    335. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012; 7(8):e42324. PMID: 22870317.
      View in: PubMed
    336. Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171. PMID: 22911754.
      View in: PubMed
    337. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012 Jul 19; 14(4):R108. PMID: 22812534.
      View in: PubMed
    338. Barwal I, Sood A, Sharma M, Singh B, Yadav SC. Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine. Colloids Surf B Biointerfaces. 2013 Jan 01; 101:510-6. PMID: 23022553.
      View in: PubMed
    339. Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Zimmerman MB, Penedo FJ, Lucci JA, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole SW, Sood AK. Social influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol. 2012 Aug 10; 30(23):2885-90. PMID: 22802321.
      View in: PubMed
    340. Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9. PMID: 22776561.
      View in: PubMed
    341. Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine influences on cancer progression. Brain Behav Immun. 2013 Mar; 30 Suppl:S19-25. PMID: 22728325.
      View in: PubMed
    342. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4. PMID: 22710075.
      View in: PubMed
    343. Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res. 2012 Aug 01; 18(15):4114-21. PMID: 22693353.
      View in: PubMed
    344. Zand B, Coleman RL, Sood AK. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am. 2012 Jun; 26(3):543-63, viii. PMID: 22520979.
      View in: PubMed
    345. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012 Oct; 33(10):1843-53. PMID: 22581827.
      View in: PubMed
    346. Liu Y, Sun Y, Broaddus R, Liu J, Sood AK, Shmulevich I, Zhang W. Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One. 2012; 7(5):e36383. PMID: 22590536.
      View in: PubMed
    347. Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Penedo F, Lubaroff DM, Sood AK, Lutgendorf SK. Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav Immun. 2012 Oct; 26(7):1037-44. PMID: 22543257.
      View in: PubMed
    348. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539.
      View in: PubMed
    349. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res. 2012 Jun 01; 18(11):3197-206. PMID: 22492981.
      View in: PubMed
    350. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544. PMID: 22966490.
      View in: PubMed
    351. Nadha HK, Salwan R, Kasana RC, Anand M, Sood A. Identification and elimination of bacterial contamination during in vitro propagation of Guadua angustifolia Kunth. Pharmacogn Mag. 2012 Apr; 8(30):93-7. PMID: 22701279.
      View in: PubMed
    352. Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol. 2012 Oct; 43(10):1638-44. PMID: 22436627.
      View in: PubMed
    353. Frumovitz M, Kriseman ML, Sun CC, Blumenthal-Barby J, Sood AK, Bodurka DC, Soliman PT. Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships. Obstet Gynecol. 2012 Mar; 119(3):504-8. PMID: 22353948.
      View in: PubMed
    354. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5. PMID: 22387451.
      View in: PubMed
    355. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8. PMID: 22335738.
      View in: PubMed
    356. Melhem-Bertrandt A, Sood AK. New directions in reducing stress effects on cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):147-9. PMID: 22307563.
      View in: PubMed
    357. Wu SY, Sood AK. New roles opined for OPCML. Cancer Discov. 2012 Feb; 2(2):115-6. PMID: 22585855.
      View in: PubMed
    358. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9. PMID: 22390757.
      View in: PubMed
    359. Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJ. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7. PMID: 22210309.
      View in: PubMed
    360. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1201-6. PMID: 22186256.
      View in: PubMed
    361. Li L, Cao XH, Chen SR, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Up-regulation of Cavß3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain. J Biol Chem. 2012 Feb 17; 287(8):6002-13. PMID: 22187436.
      View in: PubMed
    362. Sood AK, Coleman RL, Ellis LM. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):345-7. PMID: 22184398.
      View in: PubMed
    363. Berger JL, Westin SN, Fellman B, Rallapali V, Frumovitz M, Ramirez PT, Sood AK, Soliman PT. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5. PMID: 22166844.
      View in: PubMed
    364. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94. PMID: 22072418.
      View in: PubMed
    365. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18708-13. PMID: 22068913.
      View in: PubMed
    366. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011 Dec; 1(7):580-6. PMID: 22180853.
      View in: PubMed
    367. You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, Liang D, Wei W, Sood AK, Li C. Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release. J Control Release. 2012 Mar 10; 158(2):319-28. PMID: 22063003.
      View in: PubMed
    368. Lutgendorf SK, Sood AK. Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med. 2011 Nov-Dec; 73(9):724-30. PMID: 22021459.
      View in: PubMed
    369. Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 mediated ß-catenin signaling and survival in human gastro-intestinal cancer cell lines. PLoS One. 2011; 6(10):e23208. PMID: 22028766.
      View in: PubMed
    370. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011 Oct 12; 306(14):1557-65. PMID: 21990299.
      View in: PubMed
    371. Jackson DB, Sood AK. Personalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol. 2011 10 11; 8(12):735-41. PMID: 21989071.
      View in: PubMed
    372. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17. PMID: 21992853.
      View in: PubMed
    373. Matsuo K, Eno ML, Ahn EH, Shahzad MM, Im DD, Rosenshein NB, Sood AK. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol. 2011 Oct; 34(5):488-93. PMID: 20921883.
      View in: PubMed
    374. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612. PMID: 21957230.
      View in: PubMed
    375. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25. PMID: 21941283.
      View in: PubMed
    376. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37. PMID: 21806944.
      View in: PubMed
    377. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9. PMID: 21795478.
      View in: PubMed
    378. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85. PMID: 21753153.
      View in: PubMed
    379. Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011 Aug 15; 17(16):5367-78. PMID: 21737505.
      View in: PubMed
    380. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121. PMID: 21754983.
      View in: PubMed
    381. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29; 474(7353):609-15. PMID: 21720365.
      View in: PubMed
    382. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011 Jun 07; 8(8):467-77. PMID: 21647195.
      View in: PubMed
    383. Rupaimoole R, Han HD, Lopez-Berestein G, Sood AK. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011 Jun; 30(6):368-70. PMID: 21627858.
      View in: PubMed
    384. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2645-52. PMID: 21632501.
      View in: PubMed
    385. Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AK. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45. PMID: 21358280.
      View in: PubMed
    386. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia. 2011 May; 13(5):393-405. PMID: 21532880.
      View in: PubMed
    387. Lee JS, Rodríguez-Luccioni HL, Méndez J, Sood AK, Lpez-Berestein G, Rinaldi C, Torres-Lugo M. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol. 2011 May; 11(5):4153-7. PMID: 21780419.
      View in: PubMed
    388. Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AK. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun 01; 17(11):3649-59. PMID: 21531818.
      View in: PubMed
    389. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3716-26. PMID: 21512144.
      View in: PubMed
    390. Sood AK, Lutgendorf SK. Stress influences on anoikis. Cancer Prev Res (Phila). 2011 Apr; 4(4):481-5. PMID: 21464029.
      View in: PubMed
    391. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011 Apr; 13(4):309-19. PMID: 21472135.
      View in: PubMed
    392. Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918. PMID: 21445297.
      View in: PubMed
    393. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011 Apr 15; 17(8):2250-9. PMID: 21421858.
      View in: PubMed
    394. Sood AK, Wilson MT, Herzog TJ. Supporting gynecologic cancer research: the last 20 years and beyond. Gynecol Oncol. 2011 Mar; 120(3):319-20. PMID: 21320669.
      View in: PubMed
    395. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21. PMID: 21300758.
      View in: PubMed
    396. Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. Immunol Allergy Clin North Am. 2011 Feb; 31(1):109-32. PMID: 21094927.
      View in: PubMed
    397. Yadav SC, Yadav SK, Sood A, Sharma M, Singh B. Development of antidiabetic nanomedicine from stevioside. J Biomed Nanotechnol. 2011 Feb; 7(1):54-5. PMID: 21485800.
      View in: PubMed
    398. Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front Biosci (Schol Ed). 2011 Jan 01; 3:82-97. PMID: 21196359.
      View in: PubMed
    399. Lamkin DM, Lutgendorf SK, Lubaroff D, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav Immun. 2011 Mar; 25(3):555-64. PMID: 21182930.
      View in: PubMed
    400. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67. PMID: 21160526.
      View in: PubMed
    401. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14. PMID: 20948320.
      View in: PubMed
    402. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol. 2010 Dec; 6(12):1863-81. PMID: 21142861.
      View in: PubMed
    403. Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer. 2010 Dec; 1(6):277-90. PMID: 21761359.
      View in: PubMed
    404. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713.
      View in: PubMed
    405. Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011 Jan; 120(1):113-20. PMID: 21056906.
      View in: PubMed
    406. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9. PMID: 20665499.
      View in: PubMed
    407. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33. PMID: 20861284.
      View in: PubMed
    408. Lutgendorf SK, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun. 2011 Feb; 25(2):250-5. PMID: 20955777.
      View in: PubMed
    409. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99. PMID: 20889728.
      View in: PubMed
    410. Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka T. Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One. 2010 Sep 30; 5(9). PMID: 20927342.
      View in: PubMed
    411. Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK, Lubaroff DM, Lutgendorf SK. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer. 2010 Sep 15; 116(18):4410-9. PMID: 20564155.
      View in: PubMed
    412. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov 12; 285(46):35462-70. PMID: 20826776.
      View in: PubMed
    413. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010 Sep 15; 70(18):7042-52. PMID: 20823155.
      View in: PubMed
    414. Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010 Nov; 19(11):1339-54. PMID: 20815774.
      View in: PubMed
    415. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97. PMID: 20708159.
      View in: PubMed
    416. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010 Aug 09; 18(2):109-21. PMID: 20708153.
      View in: PubMed
    417. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88. PMID: 20682653.
      View in: PubMed
    418. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-73. PMID: 20664385.
      View in: PubMed
    419. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol. 2010 Sep 10; 28(26):4094-9. PMID: 20644093.
      View in: PubMed
    420. Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers TE, Goodheart MJ, Antoni MH, Sood AK, Lubaroff DM. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun. 2010 Nov; 24(8):1231-40. PMID: 20600809.
      View in: PubMed
    421. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug 01; 16(15):3910-22. PMID: 20538762.
      View in: PubMed
    422. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96. PMID: 20430760.
      View in: PubMed
    423. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010 Apr 15; 116(8):1918-25. PMID: 20166213.
      View in: PubMed
    424. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70. PMID: 20388851.
      View in: PubMed
    425. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May; 120(5):1515-23. PMID: 20389021.
      View in: PubMed
    426. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010 Apr; 9(4):985-95. PMID: 20371710.
      View in: PubMed
    427. Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010 Jun; 117(3):491-6. PMID: 20332054.
      View in: PubMed
    428. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010 May; 11(5):465-75. PMID: 20226736.
      View in: PubMed
    429. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010 Mar; 10(3):431-7. PMID: 20092424.
      View in: PubMed
    430. Merritt WM, Bar-Eli M, Sood AK. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 2010 Apr 01; 70(7):2571-4. PMID: 20179193.
      View in: PubMed
    431. Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TE. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A. 2010 Mar 23; 107(12):5681-6. PMID: 20176930.
      View in: PubMed
    432. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82. PMID: 20009575.
      View in: PubMed
    433. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010 Feb 15; 16(4):1119-28. PMID: 20145172.
      View in: PubMed
    434. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30. PMID: 20052724.
      View in: PubMed
    435. Sood AK, Coleman RL. Targeted therapy in gynecologic oncology: biology, strategy, and assessment. Gynecol Oncol. 2010 Feb; 116(2):155-6. PMID: 20109724.
      View in: PubMed
    436. Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53. PMID: 20059643.
      View in: PubMed
    437. Huang J, Hu W, Sood AK. Prognostic biomarkers in ovarian cancer. Cancer Biomark. 2010-2011; 8(4-5):231-51. PMID: 22045356.
      View in: PubMed
    438. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94. PMID: 20028751.
      View in: PubMed
    439. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72. PMID: 19829059.
      View in: PubMed
    440. Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 2009 Oct 22; 4(10):e7502. PMID: 19847298.
      View in: PubMed
    441. Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 2010 Jan; 116(1):61-5. PMID: 19840886.
      View in: PubMed
    442. Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resist Updat. 2009 Dec; 12(6):148-52. PMID: 19805003.
      View in: PubMed
    443. Cai YQ, Chen SR, Han HD, Sood AK, Lopez-Berestein G, Pan HL. Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem. 2009 Nov; 111(4):1000-10. PMID: 19780895.
      View in: PubMed
    444. Shinn EH, Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Li Y, Basen-Engquist K. Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. Palliat Support Care. 2009 Sep; 7(3):299-306. PMID: 19788771.
      View in: PubMed
    445. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603. PMID: 19738426.
      View in: PubMed
    446. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205. PMID: 19641174.
      View in: PubMed
    447. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34. PMID: 19395869.
      View in: PubMed
    448. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92. PMID: 19396818.
      View in: PubMed
    449. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009 Sep; 114(3):431-6. PMID: 19524286.
      View in: PubMed
    450. Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun; 5(5):591-600. PMID: 19519199.
      View in: PubMed
    451. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80. PMID: 19470734.
      View in: PubMed
    452. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res. 2009 May 01; 15(9):2971-8. PMID: 19383821.
      View in: PubMed
    453. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52. PMID: 19361839.
      View in: PubMed
    454. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009 Apr 15; 15(8):2695-702. PMID: 19351748.
      View in: PubMed
    455. Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80. PMID: 19416223.
      View in: PubMed
    456. Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009 Mar 01; 115(5):1021-7. PMID: 19156916.
      View in: PubMed
    457. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53. PMID: 19058181.
      View in: PubMed
    458. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol. 2009 Apr; 113(1):86-90. PMID: 19162310.
      View in: PubMed
    459. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42. PMID: 19495686.
      View in: PubMed
    460. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50. PMID: 19092150.
      View in: PubMed
    461. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle. 2008 Dec; 7(23):3747-58. PMID: 19029832.
      View in: PubMed
    462. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008 Dec 15; 14(24):8143-51. PMID: 19088029.
      View in: PubMed
    463. Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008 Nov 01; 68(21):9078-86. PMID: 18974154.
      View in: PubMed
    464. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia. 2008 Nov; 10(11):1259-67. PMID: 18953435.
      View in: PubMed
    465. Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA, Cole SW, Lubaroff DM, Sood AK. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res. 2008 Nov 01; 14(21):6839-46. PMID: 18980978.
      View in: PubMed
    466. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008 Dec 04; 27(57):7192-200. PMID: 18806828.
      View in: PubMed
    467. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA, Cole S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008 Oct 10; 26(29):4820-7. PMID: 18779606.
      View in: PubMed
    468. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46. PMID: 18765535.
      View in: PubMed
    469. Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, Pollock RE, Lev D. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res. 2008 Sep 01; 14(17):5466-75. PMID: 18765538.
      View in: PubMed
    470. Nick AM, Sood AK. The ROC 'n' role of the multiplex assay for early detection of ovarian cancer. Nat Clin Pract Oncol. 2008 Oct; 5(10):568-9. PMID: 18695710.
      View in: PubMed
    471. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58. PMID: 18632639.
      View in: PubMed
    472. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther. 2008 Jul; 7(7):1807-16. PMID: 18644993.
      View in: PubMed
    473. Sood AK, Birrer MJ. Highlights from the 2008 Annual Meeting of the American Association for Cancer Research. Gynecol Oncol. 2008 Jul; 110(1):5-6. PMID: 18595162.
      View in: PubMed
    474. Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. Brain Behav Immun. 2009 Jan; 23(1):10-5. PMID: 18638541.
      View in: PubMed
    475. Lutgendorf SK, DeGeest K, Sung CY, Arevalo JM, Penedo F, Lucci J, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SW. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun. 2009 Feb; 23(2):176-83. PMID: 18550328.
      View in: PubMed
    476. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008 Jun 01; 14(11):3372-9. PMID: 18519766.
      View in: PubMed
    477. Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD. The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res. 2008 Jun 01; 68(11):4321-30. PMID: 18519692.
      View in: PubMed
    478. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008 Jul; 7(7):1098-103. PMID: 18443431.
      View in: PubMed
    479. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2476-83. PMID: 18413840.
      View in: PubMed
    480. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PMID: 18395047.
      View in: PubMed
    481. Sanguino A, Lopez-Berestein G, Sood AK. Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 2008 Mar; 8(3):248-55. PMID: 18336345.
      View in: PubMed
    482. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 05; 100(5):359-72. PMID: 18314475.
      View in: PubMed
    483. Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun. 2008 Aug; 22(6):890-900. PMID: 18276105.
      View in: PubMed
    484. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008 Apr; 5(4):194-204. PMID: 18268546.
      View in: PubMed
    485. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20; 26(6):995-1005. PMID: 18195328.
      View in: PubMed
    486. Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20. PMID: 18182619.
      View in: PubMed
    487. Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol. 2008; 622:23-33. PMID: 18546616.
      View in: PubMed
    488. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95. PMID: 18094433.
      View in: PubMed
    489. Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Semin Cancer Biol. 2008 Jun; 18(3):164-70. PMID: 18201896.
      View in: PubMed
    490. Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007 Dec; 117(12):4044-54. PMID: 18060038.
      View in: PubMed
    491. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007 Nov 15; 67(22):10976-83. PMID: 18006843.
      View in: PubMed
    492. Landen CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007 Nov 01; 67(21):10389-96. PMID: 17974982.
      View in: PubMed
    493. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45. PMID: 17909042.
      View in: PubMed
    494. Sharma B, Joseph A, Sood A. A simple and rapid method for quantifying 2-phenoxyethanol (2-PE) in Diphtheria, Tetanus and w-Pertussis (DTwP) vaccine. Biologicals. 2008 Jan; 36(1):61-3. PMID: 17728142.
      View in: PubMed
    495. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007 Oct 12; 282(41):29919-26. PMID: 17716980.
      View in: PubMed
    496. Sood AK. Cancer in surgical scar: insights and clinical challenges. Obstet Gynecol. 2007 Aug; 110(2 Pt 2):453-4. PMID: 17666626.
      View in: PubMed
    497. Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, DeGeest K, Sood AK, Lubaroff DM. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun. 2008 Jan; 22(1):65-73. PMID: 17643954.
      View in: PubMed
    498. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res. 2007 Jul 15; 13(14):4209-17. PMID: 17634550.
      View in: PubMed
    499. Landen CN, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res. 2007 Jul 15; 13(14):4098-104. PMID: 17634535.
      View in: PubMed
    500. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007 Jun 01; 13(11):3423-30. PMID: 17545551.
      View in: PubMed
    501. Spannuth WA, Thaker PH, Sood AK. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. Am J Obstet Gynecol. 2007 Apr; 196(4):e6-9. PMID: 17403394.
      View in: PubMed
    502. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer. 2007 Apr 10; 96(7):1083-91. PMID: 17353927.
      View in: PubMed
    503. Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol. 2007 Mar; 104(3):768-78. PMID: 17306693.
      View in: PubMed
    504. Milam MR, Sood AK, King S, Bassett RL, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2007 Mar; 109(3):641-6. PMID: 17329515.
      View in: PubMed
    505. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15; 67(4):1757-68. PMID: 17308118.
      View in: PubMed
    506. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle. 2007 Feb 15; 6(4):430-3. PMID: 17312398.
      View in: PubMed
    507. Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007 Jan 15; 109(2):332-40. PMID: 17154180.
      View in: PubMed
    508. Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. Dis Markers. 2007; 23(5-6):419-31. PMID: 18057525.
      View in: PubMed
    509. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007 Jan 01; 67(1):281-8. PMID: 17210709.
      View in: PubMed
    510. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13. PMID: 17106249.
      View in: PubMed
    511. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006 Nov 01; 66(21):10357-64. PMID: 17079456.
      View in: PubMed
    512. Coleman RL, Sood AK. Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy. Curr Oncol Rep. 2006 Nov; 8(6):455-64. PMID: 17040624.
      View in: PubMed
    513. Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70. PMID: 17077358.
      View in: PubMed
    514. Merritt WM, Thaker PH, Landen CN, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther. 2006 Oct; 5(10):1357-60. PMID: 16969087.
      View in: PubMed
    515. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN, Lu C, Gershenson DM, Simpson JL, Sood AK. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther. 2006 Oct; 5(10):1369-74. PMID: 16969071.
      View in: PubMed
    516. Sood AK. Second look laparotomy for ovarian germ cell tumors: to do or not to do? J Postgrad Med. 2006 Oct-Dec; 52(4):246-7. PMID: 17191357.
      View in: PubMed
    517. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41. PMID: 16855388.
      View in: PubMed
    518. Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3. PMID: 16963111.
      View in: PubMed
    519. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res. 2006 Sep 01; 66(17):8633-9. PMID: 16951177.
      View in: PubMed
    520. Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci. 2006 Sep; 1075:230-4. PMID: 17108216.
      View in: PubMed
    521. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24. PMID: 16914580.
      View in: PubMed
    522. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8. PMID: 16880307.
      View in: PubMed
    523. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44. PMID: 16862152.
      View in: PubMed
    524. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006 Nov; 103(2):512-7. PMID: 16750560.
      View in: PubMed
    525. Sood AK. Location matters. Gynecol Oncol. 2006 Jun; 101(3):378-9. PMID: 16723288.
      View in: PubMed
    526. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Han L, Gershenson DM, Sood AK. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006 Mar 15; 12(6):1707-14. PMID: 16551853.
      View in: PubMed
    527. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006 03; 6(3):240-8. PMID: 16498446.
      View in: PubMed
    528. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI. The role of relaxin in endometrial cancer. Cancer Biol Ther. 2006 Jan; 5(1):71-7. PMID: 16322684.
      View in: PubMed
    529. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006 Jan 15; 12(2):369-75. PMID: 16428474.
      View in: PubMed
    530. Han LY, Landen CN, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):755-61. PMID: 16380413.
      View in: PubMed
    531. Thakur R, Sood A, Nagar PK, Pandey S, Sobti RC, Ahuja PS. Regulation of growth of Lilium plantlets in liquid medium by application of paclobutrazol or ancymidol, for its amenability in a bioreactor system: growth parameters. Plant Cell Rep. 2006 May; 25(5):382-91. PMID: 16369766.
      View in: PubMed
    532. Halder J, Landen CN, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8829-36. PMID: 16361572.
      View in: PubMed
    533. McDonald PG, Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, Stefanek M, Sood AK. A biobehavioral perspective of tumor biology. Discov Med. 2005 Dec; 5(30):520-6. PMID: 20704834.
      View in: PubMed
    534. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets. 2005 Dec; 9(6):1179-87. PMID: 16300469.
      View in: PubMed
    535. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005 Nov 15; 65(22):10602-12. PMID: 16288054.
      View in: PubMed
    536. Kamat AA, Sood AK. The merits of vascular targeting for gynecologic malignancies. Curr Oncol Rep. 2005 Nov; 7(6):444-50. PMID: 16221381.
      View in: PubMed
    537. Pati PK, Rath SP, Sharma M, Sood A, Ahuja PS. In vitro propagation of rose--a review. Biotechnol Adv. 2006 Jan-Feb; 24(1):94-114. PMID: 16169183.
      View in: PubMed
    538. Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005 Oct 01; 23(28):7105-13. PMID: 16192594.
      View in: PubMed
    539. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6966-71. PMID: 16203789.
      View in: PubMed
    540. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005 Aug 01; 65(15):6910-8. PMID: 16061675.
      View in: PubMed
    541. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005 Jul 15; 104(2):305-13. PMID: 15954082.
      View in: PubMed
    542. Thaker PH, Yokoi K, Jennings NB, Li Y, Rebhun RB, Rousseau DL, Fan D, Sood AK. Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal. Cancer Biol Ther. 2005 Jul; 4(7):753-8. PMID: 15970706.
      View in: PubMed
    543. Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res. 2005 Jul 01; 11(13):4923-33. PMID: 16000591.
      View in: PubMed
    544. Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol. 2005 Jun; 97(3):916-23. PMID: 15907981.
      View in: PubMed
    545. Sood AK, Coleman RL, Wolf JK, Gershenson DM. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother. 2005 Jun; 6(7):1269-75. PMID: 15957979.
      View in: PubMed
    546. Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AK. Malignant mixed mullerian tumor (MMMT) of the cervix. Gynecol Oncol. 2005 May; 97(2):442-5. PMID: 15863143.
      View in: PubMed
    547. Sood AK, Cooper BC, Sorosky JI, Ramirez PT, Levenback C. Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation. Obstet Gynecol. 2005 Mar; 105(3):514-8. PMID: 15738017.
      View in: PubMed
    548. Landen CN, Klingelhutz A, Coffin JE, Sorosky JI, Sood AK. Genomic instability is associated with lack of telomerase activation in ovarian cancer. Cancer Biol Ther. 2004 Dec; 3(12):1250-3. PMID: 15477760.
      View in: PubMed
    549. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004 Oct; 165(4):1087-95. PMID: 15466376.
      View in: PubMed
    550. Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6080-5. PMID: 15447993.
      View in: PubMed
    551. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004 Aug 01; 10(15):5145-50. PMID: 15297418.
      View in: PubMed
    552. Frausto SD, Geisler JP, Fletcher MS, Sood AK. Late recurrence of juvenile granulosa cell tumor of the ovary. Am J Obstet Gynecol. 2004 Jul; 191(1):366-7. PMID: 15295395.
      View in: PubMed
    553. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJ. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004 Apr; 190(4):899-909. PMID: 15118611.
      View in: PubMed
    554. Guven ES, Guven S, Ayhan A. Comment on "Recurrent carcinoma in situ of a neovagina". Gynecol Oncol. 2004 Feb; 92(2):728; 728-9. PMID: 14766277.
      View in: PubMed
    555. Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol. 2004 Feb; 27(1):14-8. PMID: 14758127.
      View in: PubMed
    556. Eichholz AC, Van Voorhis BJ, Sorosky JI, Smith BJ, Sood AK. Operative note dictation: should it be taught routinely in residency programs? Obstet Gynecol. 2004 Feb; 103(2):342-6. PMID: 14754706.
      View in: PubMed
    557. Godbole S, Sood A, Sharma M, Nagar PK, Ahuja PS. Starch deposition and amylase accumulation during somatic embryogenesis in bamboo (Dendrocalamus hamiltonii). J Plant Physiol. 2004 Feb; 161(2):245-8. PMID: 15022840.
      View in: PubMed
    558. Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol. 2003 Dec; 91(3):569-72. PMID: 14675678.
      View in: PubMed
    559. Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003 Nov 15; 98(10):2199-206. PMID: 14601090.
      View in: PubMed
    560. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003 Oct 01; 9(12):4514-21. PMID: 14555525.
      View in: PubMed
    561. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol. 2003 Aug 01; 21(15):2856-9. PMID: 12885801.
      View in: PubMed
    562. Bender DP, Sorosky JI, Buller RE, Sood AK. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am J Obstet Gynecol. 2003 Jul; 189(1):113-7. PMID: 12861147.
      View in: PubMed
    563. Sood AK, Hendrix MJ. The complexity of tumor vascularity. Cancer Biol Ther. 2003 May-Jun; 2(3):257-8. PMID: 12878860.
      View in: PubMed
    564. Chun ML, Buekers TE, Sood AK, Sorosky JI. Postoperative wound infection with Pasteurella multocida from a pet cat. Am J Obstet Gynecol. 2003 Apr; 188(4):1115-6. PMID: 12712125.
      View in: PubMed
    565. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther. 2002 Nov-Dec; 1(6):661-4. PMID: 12642690.
      View in: PubMed
    566. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002 Oct; 8(10):3193-7. PMID: 12374688.
      View in: PubMed
    567. Sood AK, Nygaard I, Shahin MS, Sorosky JI, Lutgendorf SK, Rao SS. Anorectal dysfunction after surgical treatment for cervical cancer. J Am Coll Surg. 2002 Oct; 195(4):513-9. PMID: 12375757.
      View in: PubMed
    568. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002 Sep; 8(9):2924-32. PMID: 12231537.
      View in: PubMed
    569. Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther. 2002 Sep-Oct; 1(5):511-7. PMID: 12496479.
      View in: PubMed
    570. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer. 2002 Aug 15; 95(4):808-15. PMID: 12209725.
      View in: PubMed
    571. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002 Jul; 100(1):59-64. PMID: 12100804.
      View in: PubMed
    572. Eichholz AC, Mahavni V, Sood AK. Allopathic and complementary alternatives to hormone replacement therapy. Expert Opin Pharmacother. 2002 Jul; 3(7):949-55. PMID: 12083994.
      View in: PubMed
    573. Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol. 2002 Jul; 86(1):85-90. PMID: 12079305.
      View in: PubMed
    574. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7. PMID: 11919241.
      View in: PubMed
    575. Lutgendorf SK, Anderson B, Ullrich P, Johnsen EL, Buller RE, Sood AK, Sorosky JI, Ritchie J. Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer. 2002 Jan 01; 94(1):131-40. PMID: 11815969.
      View in: PubMed
    576. Sood AK, Fletcher MS, Hendrix MJ. The embryonic-like properties of aggressive human tumor cells. J Soc Gynecol Investig. 2002 Jan-Feb; 9(1):2-9. PMID: 11839501.
      View in: PubMed
    577. Lowe MP, Bender D, Sood AK, Davis W, Syrop CH, Sorosky JI. Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril. 2002 Jan; 77(1):188-9. PMID: 11779615.
      View in: PubMed
    578. Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller RE. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol. 2001 Dec; 83(3):501-3. PMID: 11733962.
      View in: PubMed
    579. Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol. 2001 Dec; 83(3):599-600. PMID: 11733979.
      View in: PubMed
    580. Mahavni V, Sood AK. Hormone replacement therapy and cancer risk. Curr Opin Oncol. 2001 Sep; 13(5):384-9. PMID: 11555717.
      View in: PubMed
    581. Sood AK, Holmes R, Hendrix MJ, Buller RE. Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer. Cancer Res. 2001 Jun 01; 61(11):4371-4. PMID: 11389062.
      View in: PubMed
    582. Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol. 2001 Apr; 184(5):891-902; discussion 902-3. PMID: 11303196.
      View in: PubMed
    583. Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res. 2001 Apr; 7(4):831-8. PMID: 11309330.
      View in: PubMed
    584. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ. Molecular determinants of ovarian cancer plasticity. Am J Pathol. 2001 Apr; 158(4):1279-88. PMID: 11290546.
      View in: PubMed
    585. Lowe MP, Ault KA, Sood AK. Recurrent carcinoma in situ of a neovagina. Gynecol Oncol. 2001 Mar; 80(3):403-4. PMID: 11263940.
      View in: PubMed
    586. Mayr NA, Yuh WT, Arnholt JC, Ehrhardt JC, Sorosky JI, Magnotta VA, Berbaum KS, Zhen W, Paulino AC, Oberley LW, Sood AK, Buatti JM. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging. 2000 Dec; 12(6):1027-33. PMID: 11105046.
      View in: PubMed
    587. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000 Nov 01; 89(9):2006-17. PMID: 11064359.
      View in: PubMed
    588. Zhang SH, Sood AK, Sorosky JI, Anderson B, Buller RE. Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva. Cancer. 2000 Oct 01; 89(7):1520-5. PMID: 11013366.
      View in: PubMed
    589. Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE. Longterm central venous access in gynecologic cancer patients. J Am Coll Surg. 2000 Oct; 191(4):403-9. PMID: 11030246.
      View in: PubMed
    590. Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JI. Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer. 2000 Sep 15; 89(6):1402-11. PMID: 11002237.
      View in: PubMed
    591. Sood AK, Sorosky JI, Mayr N, Anderson B, Buller RE, Niebyl J. Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes. Obstet Gynecol. 2000 Jun; 95(6 Pt 1):832-8. PMID: 10831976.
      View in: PubMed
    592. Pertzborn S, Buekers TE, Sood AK. Hematogenous skin metastases from cervical cancer at primary presentation. Gynecol Oncol. 2000 Mar; 76(3):416-7. PMID: 10684721.
      View in: PubMed
    593. Boyd J, Narod SA. Re: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst. 1999 Sep 01; 91(17):1507-9. PMID: 10469755.
      View in: PubMed
    594. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res. 1999 Sep; 5(9):2485-90. PMID: 10499623.
      View in: PubMed
    595. Sood AK, Sorosky JI, Squatrito RC, Skilling JS, Anderson B, Buller RE. Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies. Neoplasia. 1999 Jun; 1(2):118-22. PMID: 10933045.
      View in: PubMed
    596. Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst. 1999 Feb 17; 91(4):339-46. PMID: 10050867.
      View in: PubMed
    597. Sood AK, Buller RE. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol. 1998 Aug; 92(2):312-9. PMID: 9699774.
      View in: PubMed
    598. Sood AK, Sorosky JI. Invasive cervical cancer complicating pregnancy. How to manage the dilemma. Obstet Gynecol Clin North Am. 1998 Jun; 25(2):343-52. PMID: 9629575.
      View in: PubMed
    599. Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer. 1998 May 01; 82(9):1731-7. PMID: 9576296.
      View in: PubMed
    600. Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ. Field cancerization: why late "recurrent" ovarian cancer is not recurrent. Am J Obstet Gynecol. 1998 Apr; 178(4):641-9. PMID: 9579425.
      View in: PubMed
    601. Signore CC, Sood AK, Richards DS. Second-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome. Am J Obstet Gynecol. 1998 Feb; 178(2):336-40. PMID: 9500496.
      View in: PubMed
    602. Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol. 1998 Jan; 68(1):25-8. PMID: 9454655.
      View in: PubMed
    603. Sood AK, Sorosky JI, Mayr N, Krogman S, Anderson B, Buller RE, Hussey DH. Radiotherapeutic management of cervical carcinoma that complicates pregnancy. Cancer. 1997 Sep 15; 80(6):1073-8. PMID: 9305707.
      View in: PubMed
    604. Sorosky JI, Sood AK, Buekers TE. The use of chemotherapeutic agents during pregnancy. Obstet Gynecol Clin North Am. 1997 Sep; 24(3):591-9. PMID: 9266580.
      View in: PubMed
    605. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997 Sep; 90(3):441-7. PMID: 9277659.
      View in: PubMed
    606. Rasmussen CC, Sood AK, Sorosky JI, Anderson B. Posterior exenteration through groin incision in a patient with stage III vulvar carcinoma. Gynecol Oncol. 1997 Aug; 66(2):331-4. PMID: 9264586.
      View in: PubMed
    607. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther. 1997 Jul-Aug; 4(4):239-45. PMID: 9253509.
      View in: PubMed
    608. Sood AK, Skilling JS, Buller RE. Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res. 1997 Mar 15; 57(6):1047-9. PMID: 9067268.
      View in: PubMed
    609. Sood AK, Buller RE. Genomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction. Oncogene. 1996 Dec 05; 13(11):2499-504. PMID: 8957095.
      View in: PubMed
    610. Sood AK, Sorosky JI, Krogman S, Anderson B, Benda J, Buller RE. Surgical management of cervical cancer complicating pregnancy: a case-control study. Gynecol Oncol. 1996 Dec; 63(3):294-8. PMID: 8946861.
      View in: PubMed
    611. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene. 1996 Jul 04; 13(1):117-23. PMID: 8700537.
      View in: PubMed
    612. Sood AK, Yancey M, Richards D. Prediction of fetal macrosomia using humeral soft tissue thickness. Obstet Gynecol. 1995 Jun; 85(6):937-40. PMID: 7770263.
      View in: PubMed
    613. Sood AK, Gelder MS, Huang SW, Morgan LS. Anaphylaxis to carboplatin following multiple previous uncomplicated courses. Gynecol Oncol. 1995 Apr; 57(1):131-2. PMID: 7705695.
      View in: PubMed
    614. Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition. Journal of Immunology. 196:1412-1418.
    615. Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clinical. 6:76-81.
    616. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17:1621-1631.
    617. The Kim/Alvarez article reviewed. Oncology. 14:1336-1338.
    618. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. 13:2395-2402.
    619. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncology. 12:1439-1456.
    620. Targeted Therapy and Molecular Genetics. 539-560.
    621. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene.
    622. PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer. Molecular Cancer Therapeutics. 14:1466-1475.
    623. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520:697-701.
    624. Classification of ovarian cancer. Advances in Experimental Medicine and Biology. 622:23-33.
    625. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research. 22:1713-1724.
    626. Pathology in practice. Journal of the American Veterinary Medical Association. 249:1149-1151.
    627. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene.
    628. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecologic Oncology. 141:57-64.
    629. CuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal Therapy. ACS Nano. 9:7085-7096.
    630. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene.
    631. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7.
    632. The value of CA-125 levels in the management of endometrial cancer. Contemporary Reviews in Obstetrics and Gynaecology. 10:135-140.
    633. Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer. 121:3543-3550.
    634. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain, Behavior, and Immunity.
    635. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Scientific Reports. 6.
    636. Targeting therapies in cancer. 167-182.
    637. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell.
    638. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation. 126:1885-1896.
    639. BRCA1 and BRCA2 mutations in ovarian cancer - Reply. JAMA - Journal of the American Medical Association. 307:360-361.
    640. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 63:159-172.
    641. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Research. 76:6320-6330.
    642. The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6.
    643. Role of video-assisted thoracoscopy in advanced ovarian cancer. International Journal of Gynecological Cancer. 26:801-806.
    644. Differentiation therapy for hepatocellular carcinoma. Hepatology.
    645. Stress and the spread of ovarian cancer in mice. Cancer Biology and Therapy. 5:898.
    646. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research. 76:7194-7207.
    647. Mind-Body Practices in Cancer Care. Current Oncology Reports. 16.
    648. MiRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discovery. 6:235-246.
    649. MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. Journal of Pathology. 241:67-79.
    650. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology and Oncology. 9.
    651. Neuroendocrine regulation of cancer progression. 233-249.
    652. Morph-X-select. BioTechniques. 61:249-259.
    653. Polypropylene mesh erosion into the bowel and vagina after abdominal sacral colpopexy. Journal of Pelvic Medicine and Surgery. 12:45-47.
    654. Precision nanomedicine using dual PET and MR temperature imaging-guided photothermal therapy. Journal of Nuclear Medicine. 57:1778-1783.
    655. Psychoneuroimmunology and Cancer.
    656. Platelets are not hyperreactive in patients with ovarian cancer. Platelets. 1-3.
    657. Erratum. International Journal of Gynecological Pathology. 26:205.
    658. Rethinking ovarian cancer II. Nature Reviews Cancer. 15:668-679.
    659. A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets. 1-4.
    660. Regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT ativation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS One. 10.
    661. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 6.
    662. Preclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews.
    663. Carcinoma of the bartholin gland. International Journal of Gynecological Cancer. 26:785-789.
    664. Erratum. Journal of Clinical Investigation. 123:4980.
    665. Cancer Epidemiology Biomarkers and Prevention. 25:1587-1594.
    666. Molecular pathways. Clinical Cancer Research. 21:955-961.
    667. Regulating the stability and localization of CDK inhibitor p27Kip1 via CSN6-COP1 axis. Cell Cycle. 14:2265-2273.
    668. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 7:15093-15104.
    669. RNA-targeted therapeutics in cancer clinical trials. Cancer Treatment Reviews. 50:35-47.
    670. Evoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Research. 44:8052-8064.
    671. Dicer and Drosha in Ovarian Cancer. New England Journal of Medicine. 360:1151.
    672. Metastatic Breast Cancer to the Uterus and Cervix. Journal of Gynecologic Surgery. 19:145-147.
    673. Inhibition of the src oncogene. 95-107.
    674. Dll4 Inhibition plus Aflibercept markedly reduces ovarian tumor growth. Molecular Cancer Therapeutics. 15:1344-1352.
    675. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24:685-700.
    676. Depression and risk of epithelial ovarian cancer. Gynecologic Oncology. 139:481-486.
    677. Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer. Molecular Cancer Therapeutics. 15:2894-2904.
    678. Targeting c-MYC in platinum-resistant ovarian cancer. Molecular Cancer Therapeutics. 14:2260-2269.
    679. RNAi in Cancer Therapy. 271-307.
    680. Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer [Cancer Cell 23 (2013) 186-199]. Cancer Cell. 23:705.
    681. The authors reply. New England Journal of Medicine. 366:1840.
    682. Developing hyperpolarized silicon particles for advanced biomedical imaging applications.
    683. Ogilvie's syndrome complicating low colorectal anastomosis 3 years after intraperitoneal 32P. Journal of Gynecologic Techniques. 6:65-67.
    684. Depression and oropharynx cancer outcome. Psychosomatic Medicine. 78:38-48.
    685. Nanotechnology. Clinical Cancer Research. 21:3121-3130.
    686. Erratum. Oncogene. 35:801.
    687. SnapShot. Cell Metabolism. 23:388-388e1.
    688. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 121:3444-3451.
    689. Thrombosis in cancer. Cancer Research. 76:3671-3675.
    690. Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. Journal of Medical Imaging. 3.
    691. Nasoenteric Tube Complication. Nutrition in Clinical Practice. 13:40-42.
    692. Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells. Frontiers in Oncology. 3 MAR.
    693. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. International Journal of Cancer.
    694. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes and Control. 27:661-668.
    695. Assessment of In vivo siRNA delivery in cancer mouse models. 189-197.
    696. Association of somatic mutations of ADAMTS genes with chemotherapy sensitivity and survival in high-grade serous ovarian carcinoma. JAMA oncology. 1:486-494.
    697. The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics. 16:1337-1351.
    698. Targeting the tumour microenvironment in ovarian cancer. European Journal of Cancer. 56:131-143.
    699. Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 112:14266-14271.
    700. Human Papillomavirus DNA in LEEP Plume. Infectious Diseases in Obstetrics and Gynecology. 2:167-170.
    701. Erratum. Journal of Clinical Investigation. 123:5411.
    702. Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. International Journal of Nanomedicine. 11:5729-5742.
    703. Erratum. Gynecologic Oncology. 130:252-253.
    704. SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget. 7:33179-33191.
    705. TEMPORARY REMOVAL. Gynecologic Oncology.
    706. Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108.
    707. A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Molecular Systems Biology. 11:1-17.
    708. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene.
    709. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecologic Oncology.
    710. Anti-vascular therapies in ovarian cancer. Cancer and Metastasis Reviews. 34:19-40.
    711. Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent antiangiogenic activity in ovarian cancer. Molecular Cancer Therapeutics. 14:2677-2686.
    712. NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. Oncotarget. 7:47576-47585.
    713. Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Molecular Therapy - Nucleic Acids. 2.
    714. Association of low-dose aspirin and survival of women with endometrial cancer. Obstetrics and Gynecology. 128:127-137.
    715. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 7:20825-20839.
    716. Profiling long noncoding RNA expression using custom-designed microarray. 33-41.
    717. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clinical Cancer Research. 21:2127-2137.
    718. Immunological and pleiotropic effects of individual β-blockers and their relevance in cancer therapies. Expert Opinion on Investigational Drugs. 1-5.
    719. Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent. Scientific Reports. 6.
    720. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. 15:1493-1504.
    721. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.
    722. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene.
    723. Loss of heterozygosity (LOH) as a prognostic factor in ovarian cancer. CME Journal of Gynecologic Oncology. 4:189-191.
    724. Primary ovarian leiomyomas. Journal of Gynecologic Surgery. 15:55-59.
    725. Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Molecular Cancer Therapeutics. 15:618-627.
    726. Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 28:529-540.
    727. Biology and genetics. 2-38.
    728. EBioMedicine. 12:34-42.
    729. Tumor T<inf>1</inf> relaxation time for assessing response to bevacizumab anti-angiogenic therapy in a mouse ovarian cancer model. PLoS One. 10.
    730. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 7:25930-25948.
    731. Targeting approaches for nanoparticles. 64-77.
    732. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.
    733. Cancer Cell. 29:874-888.
    734. Correction. Breast Cancer Research. 14.
    735. Stress related neuroendocrine influences in ovarian cancer. Current Cancer Therapy Reviews. 8:100-109.
    736. XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research. 21:3286-3297.
    737. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Obstetrical and Gynecological Survey. 67:164-165.
    738. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertility and Sterility.
    739. Erratum. Nature Communications. 4.
    740. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 6:29161-29177.
    741. Ovarian cancer. Nature Reviews Disease Primers. 2:1-22.
    SOOD's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description